PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 214 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is 1.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,596,001 | -40.4% | 182,399 | -22.1% | 0.00% | -20.0% |
| Q2 2023 | $9,388,160 | -6.3% | 234,294 | -4.5% | 0.01% | -16.7% |
| Q1 2023 | $10,016,529 | +9.8% | 245,443 | +3.8% | 0.01% | +20.0% |
| Q4 2022 | $9,126,091 | -26.6% | 236,366 | +1.1% | 0.01% | -37.5% |
| Q3 2022 | $12,434,000 | -6.5% | 233,760 | +2.5% | 0.01% | +14.3% |
| Q2 2022 | $13,297,000 | -28.3% | 228,064 | -6.2% | 0.01% | -22.2% |
| Q1 2022 | $18,556,000 | +34.1% | 243,125 | +5.7% | 0.01% | +50.0% |
| Q4 2021 | $13,840,000 | +2.9% | 230,011 | -4.3% | 0.01% | 0.0% |
| Q3 2021 | $13,454,000 | -19.3% | 240,244 | -12.6% | 0.01% | -25.0% |
| Q2 2021 | $16,671,000 | +1.9% | 274,741 | +17.7% | 0.01% | -11.1% |
| Q1 2021 | $16,367,000 | +2.6% | 233,500 | -12.4% | 0.01% | -10.0% |
| Q4 2020 | $15,949,000 | -15.8% | 266,526 | -15.4% | 0.01% | -23.1% |
| Q3 2020 | $18,935,000 | -13.8% | 314,927 | -24.8% | 0.01% | -23.5% |
| Q2 2020 | $21,972,000 | +35.3% | 418,767 | -13.5% | 0.02% | +13.3% |
| Q1 2020 | $16,242,000 | -35.8% | 484,386 | -13.3% | 0.02% | -6.2% |
| Q4 2019 | $25,298,000 | +116.2% | 558,486 | +81.7% | 0.02% | +100.0% |
| Q3 2019 | $11,701,000 | -67.0% | 307,429 | -62.3% | 0.01% | -61.9% |
| Q2 2019 | $35,450,000 | +11.6% | 815,188 | -2.3% | 0.02% | +10.5% |
| Q1 2019 | $31,757,000 | +87.8% | 834,433 | +112.3% | 0.02% | +58.3% |
| Q4 2018 | $16,906,000 | -58.4% | 393,035 | -52.4% | 0.01% | 0.0% |
| Q3 2018 | $40,610,000 | +27.7% | 826,290 | -16.7% | 0.01% | +33.3% |
| Q2 2018 | $31,799,000 | +256.4% | 992,202 | +246.3% | 0.01% | +125.0% |
| Q1 2018 | $8,922,000 | -42.5% | 286,519 | -15.7% | 0.00% | -60.0% |
| Q4 2017 | $15,516,000 | +32.0% | 339,933 | +8.6% | 0.01% | +25.0% |
| Q3 2017 | $11,756,000 | -2.8% | 313,147 | +23.5% | 0.01% | -11.1% |
| Q2 2017 | $12,095,000 | +232.2% | 253,612 | +217.5% | 0.01% | +200.0% |
| Q1 2017 | $3,641,000 | -75.5% | 79,878 | -82.6% | 0.00% | -75.0% |
| Q4 2016 | $14,858,000 | -31.9% | 460,059 | -27.9% | 0.01% | -20.0% |
| Q3 2016 | $21,818,000 | +114.3% | 637,651 | +111.2% | 0.02% | +114.3% |
| Q2 2016 | $10,179,000 | -33.5% | 301,850 | +4.4% | 0.01% | -41.7% |
| Q1 2016 | $15,309,000 | -32.7% | 289,018 | -2.4% | 0.01% | -25.0% |
| Q4 2015 | $22,745,000 | +40.5% | 296,232 | -24.8% | 0.02% | +23.1% |
| Q3 2015 | $16,189,000 | -26.6% | 393,942 | +26.4% | 0.01% | -7.1% |
| Q2 2015 | $22,041,000 | -56.0% | 311,699 | -44.8% | 0.01% | -54.8% |
| Q1 2015 | $50,133,000 | +44.0% | 564,263 | +43.6% | 0.03% | +47.6% |
| Q4 2014 | $34,826,000 | -12.9% | 392,830 | -4.8% | 0.02% | -16.0% |
| Q3 2014 | $39,996,000 | -5.2% | 412,703 | -10.1% | 0.02% | -13.8% |
| Q2 2014 | $42,172,000 | +14.2% | 459,122 | -13.0% | 0.03% | +11.5% |
| Q1 2014 | $36,935,000 | +23.7% | 527,737 | +1.6% | 0.03% | +23.8% |
| Q4 2013 | $29,857,000 | +66.3% | 519,508 | +39.1% | 0.02% | +61.5% |
| Q3 2013 | $17,952,000 | – | 373,562 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |